GO:1900280 negative regulation of CD4-positive, alpha-beta T cell costimulation: Immune Checkpoint Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900280 describes any process that stops, prevents, or reduces the frequency, rate, or extent of CD4-positive, alpha-beta T cell costimulation.
• This term is a biological_process ontology entry and is distinct from positive regulation or the costimulation process itself.
• Key regulatory mechanisms involve inhibitory receptors such as PD-1 and cytokines such as IFN-alpha/beta that dampen CD4+ T cell activation.
• Dysregulation of this process contributes to autoimmunity, chronic infection, and tumor immune evasion.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect the causal role of individual genes in this pathway.
• Understanding GO:1900280 aids in the development of immunotherapies targeting T cell costimulation checkpoints.
Description
The Gene Ontology (GO) term GO:1900280, negative regulation of CD4-positive, alpha-beta T cell costimulation, defines a critical biological process that restrains the activation of helper T cells. Costimulation is a secondary signal required for full T cell activation, and its negative regulation ensures immune homeostasis and prevents excessive inflammation. This process is fundamental to understanding how the immune system balances protective immunity with tolerance. Researchers studying autoimmune diseases, chronic infections, and cancer immunology require a precise understanding of the molecular players that inhibit CD4+ T cell costimulation. This article synthesizes authoritative GO annotations and published literature to provide a research-grade overview of the mechanisms, genes, and experimental models relevant to GO:1900280.
negative regulation of CD4-positive, alpha-beta T cell costimulation At A Glance
| GO ID | GO:1900280 |
|---|---|
| GO term | negative regulation of CD4-positive, alpha-beta T cell costimulation |
| Ontology | biological_process |
| Synonym | inhibition of CD4-positive, alpha beta T cell costimulation |
| Major function | Dampening of costimulatory signals required for full CD4+ T cell activation |
| Related processes | T cell activation, immune tolerance, cytokine signaling |
| Cellular context | T cell-APC immunological synapse, cytokine microenvironment |
| Key regulators | PD-1, IFN-alpha/beta, regulatory T cells |
What Is GO:1900280?
GO:1900280 encompasses any biological process that stops, prevents, or reduces the frequency, rate, or extent of CD4-positive, alpha-beta T cell costimulation. In other words, it includes molecular events that dampen the secondary activating signals delivered to conventional CD4+ T cells, thereby limiting their full activation and effector functions.
Why Is negative regulation of CD4-positive, alpha-beta T cell costimulation Important in Cell Biology?
Negative regulation of CD4-positive, alpha-beta T cell costimulation is essential for preventing autoimmunity and limiting immunopathology during infection. It also plays a central role in tumor immune evasion, where cancer cells exploit these inhibitory pathways to suppress anti-tumor immunity. Understanding this process is therefore critical for developing targeted immunotherapies, including checkpoint inhibitors and tolerance-inducing vaccines.
• Prevents autoimmune responses by restraining overactive CD4+ T cells.
• Limits tissue damage during chronic infections.
• Facilitates tumor immune evasion via inhibitory receptors like PD-1.
• Modulates vaccine-induced protective immunity.
• Influences T cell development and selection in the thymus.
• Regulates cytokine production such as IFN-gamma and IL-10.
• Impacts postsurgical fibrosis through PD-1 pathways.
• Affects memory T cell responses via IFN-alpha/beta signaling.
• Provides targets for checkpoint blockade in cancer therapy.
• Guides design of tolerance-inducing therapies for transplantation.
What Happens During negative regulation of CD4-positive, alpha-beta T cell costimulation?
Inhibitory Receptor Engagement
In simple terms: Inhibitory receptors on T cells act like brakes that stop activation signals.
Negative regulation of CD4+ T cell costimulation often begins with the engagement of inhibitory receptors such as programmed death-1 (PD-1) on T cells by their ligands. This engagement recruits phosphatases that dephosphorylate key signaling intermediates, thereby dampening costimulatory pathways. This mechanism is crucial for maintaining peripheral tolerance and preventing autoimmunity.
Cytokine-Mediated Suppression
In simple terms: Certain cytokines can directly reduce the ability of T cells to receive costimulatory signals.
Cytokines such as IFN-alpha/beta can regulate IL-2 secretion in human CD4+ central memory T cells in a T-bet-independent manner, thereby limiting their costimulatory responsiveness. This cytokine-mediated suppression is important for controlling immune responses during viral infections and may contribute to T cell exhaustion in chronic diseases.
Regulatory T Cell Interference
In simple terms: Regulatory T cells can suppress the activation of conventional T cells.
CD4+CD25+ regulatory T cells develop through at least two distinct mechanisms and can inhibit the costimulation of conventional CD4+ T cells. They achieve this through contact-dependent mechanisms and the secretion of inhibitory cytokines such as IL-10 and TGF-beta, which directly interfere with costimulatory signaling.
Thymic Selection and Development
In simple terms: The thymus shapes T cells, and negative regulation ensures that only safe T cells mature.
During thymocyte development, expression of T cell receptor beta and CD3 epsilon correlates with maturation to the CD4+8+ stage, and negative regulatory processes prevent the intrathymic development of innate CD8 T cells. This developmental checkpoint is essential for establishing a self-tolerant T cell repertoire.
Impact on Effector Cytokine Production
In simple terms: Negative regulation can change the mix of cytokines produced by T cells.
In response to pathogens such as Mycobacterium tuberculosis, CD4+ alphabeta TCR+ T cells differentially regulate IFN-gamma, TNF-alpha, and IL-10 production. Negative regulation of costimulation can skew this cytokine profile, affecting the outcome of infection and the development of protective immunity.
Key Genes Involved in GO:1900280 negative regulation of CD4-positive, alpha-beta T cell costimulation
The following genes and proteins are central to the negative regulation of CD4-positive, alpha-beta T cell costimulation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDCD1 (PD-1) | Inhibitory receptor that dampens T cell costimulation | Target for cancer immunotherapy; regulates fibrosis |
| CD4 | Coreceptor defining CD4+ T cells | Essential for MHC class II-restricted costimulation |
| CD3E | Signaling subunit of the TCR complex | Correlates with thymocyte development |
| IFNA1/IFNB1 | Type I interferons that suppress IL-2 secretion | Regulate memory T cell costimulation |
| IL2 | Key T cell growth factor | Downregulated by negative costimulatory signals |
| IL10 | Anti-inflammatory cytokine | Produced by T cells in response to infection |
| IFNG | Pro-inflammatory cytokine | Differentially regulated in CD4+ T cells |
| TNF | Pro-inflammatory cytokine | Modulated during mycobacterial infection |
| BCL11B | Transcription factor in T cell development | Prevents innate CD8 T cell development |
| FOXP3 | Master regulator of regulatory T cells | Mediates suppression of costimulation |
| CD25 (IL2RA) | Alpha chain of IL-2 receptor | Marks regulatory T cells |
| TGFB1 | Immunosuppressive cytokine | Inhibits T cell costimulation |
| CTLA4 | Inhibitory receptor | Competes with CD28 for costimulatory ligands |
| LAG3 | Inhibitory receptor | Negatively regulates T cell activation |
| HAVCR2 (TIM-3) | Inhibitory receptor | Suppresses T cell responses |
| TIGIT | Inhibitory receptor | Dampens costimulation in tumors |
| VSIR (VISTA) | Inhibitory ligand/receptor | Suppresses CD4+ T cell activation |
How Is negative regulation of CD4-positive, alpha-beta T cell costimulation Regulated?
The negative regulation of CD4-positive, alpha-beta T cell costimulation is itself tightly controlled by various factors. Inhibitory receptors such as PD-1 are induced upon T cell activation and their expression is regulated by transcription factors like NFAT and NF-kB. Cytokines such as IFN-alpha/beta can upregulate these inhibitory pathways, creating a feedback loop that limits excessive inflammation. Additionally, regulatory T cells can actively suppress costimulation through contact-dependent and cytokine-mediated mechanisms. The balance between positive and negative costimulatory signals determines the outcome of T cell activation.
negative regulation of CD4-positive, alpha-beta T cell costimulation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDCD1 | Autoimmunity, cancer immune evasion | PD-1 knockout mice; tumor challenge models |
| IFNB1 | Viral infections, T cell exhaustion | IFN-alpha/beta receptor knockout mice |
| IL10 | Tuberculosis, chronic inflammation | IL-10 reporter mice; infection models |
| FOXP3 | IPEX syndrome, autoimmunity | Scurfy mice; regulatory T cell depletion |
| BCL11B | T cell development, leukemia | Conditional knockout mice |
Autoimmunity and Chronic Inflammation
Defects in the negative regulation of CD4+ T cell costimulation can lead to uncontrolled T cell activation and autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and type 1 diabetes. For example, deficiency in PD-1 signaling results in exacerbated experimental autoimmune encephalomyelitis. Understanding these pathways is crucial for developing therapies that restore tolerance.
Cancer Immune Evasion
Tumors often exploit negative costimulatory pathways to evade immune destruction. Upregulation of PD-L1 on tumor cells engages PD-1 on CD4+ T cells, suppressing their activation and effector functions. Blockade of this interaction with checkpoint inhibitors has revolutionized cancer therapy, highlighting the clinical importance of GO:1900280.
Chronic Infections
In chronic infections such as tuberculosis, negative regulation of CD4+ T cell costimulation can impair protective immunity. Mycobacterium tuberculosis infection induces IL-10 and other inhibitory signals that dampen T cell responses, contributing to bacterial persistence. Modulating these pathways may improve vaccine efficacy.
From negative regulation of CD4-positive, alpha-beta T cell costimulation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X inhibit CD4+ T cell costimulation? | CRISPR knockout in primary human T cells or Jurkat cells |
| Does a point mutation in gene Y alter inhibitory function? | CRISPR point mutation knock-in in T cell lines |
| How does overexpression of gene Z affect T cell activation? | Lentiviral overexpression in primary CD4+ T cells |
| What is the interactome of inhibitory receptor PD-1? | Tagged knock-in (e.g., APEX2) followed by proximity labeling |
| Can CRISPR library screening identify novel negative regulators? | Genome-wide CRISPR knockout screen in primary T cells |
| Does a disease-associated SNP in gene A affect costimulation? | CRISPR knock-in of SNP in iPSC-derived T cells |
How to Study the negative regulation of CD4-positive, alpha-beta T cell costimulation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene essentiality for negative regulation | Identify novel inhibitory pathways |
| RNA-seq | Transcriptional changes | Define gene expression signatures |
| Phospho-flow | Signaling protein phosphorylation | Quantify TCR signaling strength |
| Proteomics (AP-MS) | Protein interactions | Map inhibitory receptor complexes |
| Flow cytometry | Surface markers and cytokines | Assess T cell activation status |
| ELISPOT | Cytokine-secreting cells | Measure antigen-specific responses |
| ATAC-seq | Chromatin accessibility | Identify regulatory elements |
| CRISPRi/CRISPRa | Gene repression/activation | Fine-tune gene expression |
CRISPR Knockout Screening
Genome-wide CRISPR knockout screens can identify genes whose loss enhances or suppresses CD4+ T cell costimulation. This unbiased approach has uncovered novel negative regulators and potential drug targets.
RNA Sequencing (RNA-seq)
RNA-seq of CD4+ T cells under costimulatory or inhibitory conditions reveals transcriptomic changes that define the negative regulation process. It can identify genes upregulated by PD-1 engagement or IFN-alpha/beta treatment.
Flow Cytometry and Phospho-Flow
Flow cytometry measures surface markers and intracellular cytokines at the single-cell level. Phospho-flow can quantify signaling intermediates to assess the strength of costimulatory signals and their negative regulation.
Proteomics and Immunoprecipitation
Mass spectrometry-based proteomics can map protein-protein interactions at the immunological synapse, identifying components of the negative regulatory machinery. Immunoprecipitation of inhibitory receptors followed by mass spectrometry reveals their binding partners.
How CRISPR Can Be Used to Study GO:1900280 negative regulation of CD4-positive, alpha-beta T cell costimulation
Knockout
CRISPR knockout of candidate genes in primary CD4+ T cells or cell lines can determine whether a gene is required for the negative regulation of costimulation. For example, knocking out PDCD1 would be expected to enhance T cell activation, confirming its inhibitory role.
Point Mutation
Introducing precise point mutations via CRISPR can model disease-associated variants or disrupt specific functional domains. This helps dissect the molecular mechanisms by which a gene product regulates costimulation without completely abolishing its expression.
Knock-in
Knock-in of reporter genes (e.g., fluorescent proteins) or epitope tags allows tracking of gene expression and protein localization. Tagged knock-in of inhibitory receptors can facilitate interactome studies and live-cell imaging.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can increase gene dosage to study gain-of-function effects. Overexpressing a negative regulator can suppress CD4+ T cell costimulation, validating its function.
How EDITGENE Supports negative regulation of CD4-positive, alpha-beta T cell costimulation Research
Researchers studying negative regulation of CD4-positive, alpha-beta T cell costimulation-related genes often need to determine whether a candidate gene is causally involved in this process. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery, from knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of CD4-positive, alpha-beta T cell costimulation research.
Frequently Asked Questions About negative regulation of CD4-positive, alpha-beta T cell costimulation
What is GO:1900280?
GO:1900280 is a Gene Ontology term for any process that stops, prevents, or reduces the frequency, rate, or extent of CD4-positive, alpha-beta T cell costimulation.
What genes are involved in negative regulation of CD4-positive, alpha-beta T cell costimulation?
Key genes include PDCD1 (PD-1), CTLA4, FOXP3, IL10, and IFNB1, among others.
How is CD4+ T cell costimulation negatively regulated?
It is regulated by inhibitory receptors like PD-1, cytokines such as IFN-alpha/beta, and regulatory T cells.
Why is negative regulation of CD4+ T cell costimulation important?
It prevents autoimmunity, limits immunopathology, and is exploited by tumors for immune evasion.
What diseases are associated with defects in this process?
Autoimmune diseases, chronic infections like tuberculosis, and cancer.
What experimental models are used to study GO:1900280?
CRISPR knockout mice, primary human T cell cultures, and genome-wide CRISPR screens.
How can CRISPR help study negative regulation of CD4+ T cell costimulation?
CRISPR enables knockout, knock-in, and overexpression of candidate genes to test their function in T cell activation.
What is the role of PD-1 in this process?
PD-1 is an inhibitory receptor that dampens costimulatory signals and is a target for cancer immunotherapy.
Can cytokines regulate CD4+ T cell costimulation?
Yes, IFN-alpha/beta can suppress IL-2 secretion in memory CD4+ T cells, thereby negatively regulating costimulation.
What services does EDITGENE offer for studying this pathway?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services.
Conclusion
GO:1900280, negative regulation of CD4-positive, alpha-beta T cell costimulation, is a fundamental biological process that maintains immune homeostasis and shapes responses to infection and cancer. Its dysregulation underlies numerous diseases, making it a prime target for therapeutic intervention. Leveraging CRISPR-based models and EDITGENE's services will accelerate the discovery of novel regulators and drug targets in this pathway.
References
- 1. Levelt CN et al.. 1993. Regulation of thymocyte development through CD3. II. Expression of T cell receptor beta CD3 epsilon and maturation to the CD4+8+ stage are highly correlated in individual thymocytes.. J Exp Med 178(6):1867-75 PMID: 7504052
- 2. Suto A et al.. 2002. CD4(+)CD25(+) T-cell development is regulated by at least 2 distinct mechanisms.. Blood 99(2):555-60 PMID: 11781238
- 3. Derrick SC et al.. 2007. Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine.. Immunology 120(2):192-206 PMID: 17076705
- 4. Tsukaguchi K et al.. 1999. Differential regulation of IFN-gamma, TNF-alpha, and IL-10 production by CD4(+) alphabetaTCR+ T cells and vdelta2(+) gammadelta T cells in response to monocytes infected with Mycobacterium tuberculosis-H37Ra.. Cell Immunol 194(1):12-20 PMID: 10357876
- 5. Hirose S et al.. 2015. Bcl11b prevents the intrathymic development of innate CD8 T cells in a cell intrinsic manner.. Int Immunol 27(4):205-15 PMID: 25422283
- 6. Holsti MA et al.. 2004. Regulation of postsurgical fibrosis by the programmed death-1 inhibitory pathway.. J Immunol 172(9):5774-81 PMID: 15100324
- 7. Chen FL et al.. 1996. Deficient CD4+ T cell proliferation in the class 1 MHC-restricted 2C TCR-transgenic mouse.. J Immunol 156(6):2036-44 PMID: 8690890
- 8. Davis AM et al.. 2008. Cutting edge: a T-bet-independent role for IFN-alpha/beta in regulating IL-2 secretion in human CD4+ central memory T cells.. J Immunol 181(12):8204-8 PMID: 19050236
